Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Wong

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Targeted Oncology|June 14, 2022
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis InhibitorsJoan R E Choo, Yi-Hua Jan, Samuel G W Ow, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
The Lancet Regional Health. Western Pacific|July 23, 2025
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline <i>APOBEC3B</i> deletion: results of the phase II AUROR studyGwo Fuang Ho, Soo Chin Lee, Anita Zarina Bustam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Therapeutic Advances in Medical Oncology|April 18, 2022
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesJingshan Ho, Valerie Heong, Wei Peng Yong, et al.
Frontiers in Oncology|October 11, 2021
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine InitiativesSneha Rajiv Jain, Wilson Sim, Cheng Han Ng, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Targeted Oncology|June 14, 2022
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis InhibitorsJoan R E Choo, Yi-Hua Jan, Samuel G W Ow, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
The Lancet Regional Health. Western Pacific|July 23, 2025
Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline <i>APOBEC3B</i> deletion: results of the phase II AUROR studyGwo Fuang Ho, Soo Chin Lee, Anita Zarina Bustam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Therapeutic Advances in Medical Oncology|April 18, 2022
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesJingshan Ho, Valerie Heong, Wei Peng Yong, et al.
Frontiers in Oncology|October 11, 2021
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine InitiativesSneha Rajiv Jain, Wilson Sim, Cheng Han Ng, et al.
Pageof 6